Additionally, the 36-month beta value for INAB is -0.06. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for INAB is 32.04M and currently, short sellers hold a 0.55% ratio of that float. The average trading volume of INAB on October 21, 2024 was 300.34K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INAB) stock’s latest price update
The stock price of IN8bio Inc (NASDAQ: INAB) has jumped by 17.77 compared to previous close of 0.23. Despite this, the company has seen a gain of 20.39% in its stock price over the last five trading days. globenewswire.com reported 2024-09-04 that Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. Suspending enrollment of Phase 2 clinical trial of INB-400 in newly diagnosed GBM; will continue to monitor patients for long-term remissions and overall survival in both INB-400 and INB-200 at UAB.
INAB’s Market Performance
INAB’s stock has risen by 20.39% in the past week, with a monthly drop of -15.60% and a quarterly drop of -68.94%. The volatility ratio for the week is 8.19% while the volatility levels for the last 30 days are 8.86% for IN8bio Inc The simple moving average for the past 20 days is 4.78% for INAB’s stock, with a -70.48% simple moving average for the past 200 days.
Analysts’ Opinion of INAB
Many brokerage firms have already submitted their reports for INAB stocks, with Laidlaw repeating the rating for INAB by listing it as a “Buy.” The predicted price for INAB in the upcoming period, according to Laidlaw is $7.50 based on the research report published on March 18, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see INAB reach a price target of $14. The rating they have provided for INAB stocks is “Buy” according to the report published on August 30th, 2022.
INAB Trading at -29.11% from the 50-Day Moving Average
After a stumble in the market that brought INAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.07% of loss for the given period.
Volatility was left at 8.86%, however, over the last 30 days, the volatility rate increased by 8.19%, as shares sank -13.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.39% lower at present.
During the last 5 trading sessions, INAB rose by +20.39%, which changed the moving average for the period of 200-days by -78.15% in comparison to the 20-day moving average, which settled at $0.2586. In addition, IN8bio Inc saw -80.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INAB
Current profitability levels for the company are sitting at:
- -8.54 for the present operating margin
- 0.32 for the gross margin
The net margin for IN8bio Inc stands at -8.53. The total capital return value is set at -1.81. Equity return is now at value -180.45, with -122.41 for asset returns.
Based on IN8bio Inc (INAB), the company’s capital structure generated 0.3 points at debt to capital in total, while cash flow to debt ratio is standing at -4.17. The debt to equity ratio resting at 0.43. The interest coverage ratio of the stock is -54.27.
Currently, EBITDA for the company is -28.5 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 2.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.66.
Conclusion
In conclusion, IN8bio Inc (INAB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
